본문 바로가기
KERD
논문KCI 등재

The Role of Inflammasome-Associated Innate Immune Receptors in Cancer

Ruby E. Dawson|Brendan J. Jenkins
대한면역학회 (The Korean Association of Immunologists)|2024.10|Immune Network|제24권 제5호|pp. 1-23|DOI 10.4110/in.2024.24.e38

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

CancerInflammationInnate immunityInflammasomesPattern recognition receptors

초록

Dysregulated activation of the innate immune system is a critical driver of chronic inflammation that is associated with at least 30% of all cancers. Innate immunity can also exert tumour-promoting effects (e.g. proliferation) directly on cancer cells in an intrinsic manner. Conversely, innate immunity can influence adaptive immunity-based anti-tumour immune responses via Ag-presenting dendritic cells that activate natural killer and cytotoxic T cells to eradicate tumours. While adaptive anti-tumour immunity has underpinned immunotherapy approaches with immune checkpoint inhibitors and chimeric Ag receptor-T cells, the clinical utility of innate immunity in cancer is underexplored. Innate immune responses are governed by pattern recognition receptors, which comprise several families, including Toll-like, nucleotide-binding oligomerization domain-containing (NOD)-like and absent-in-melanoma 2 (AIM2)-like receptors. Notably, a subset of NOD-like and AIM2-like receptors can form large multiprotein “inflammasome” complexes which control maturation of biologically active IL-1β and IL-18 cytokines. Over the last decade, it has emerged that inflammasomes can coordinate contrasting pro- and anti-tumour responses in cancer and non-cancer (e.g. immune, stromal) cells. Considering the importance of inflammasomes to the net output of innate immune responses, here we provide an overview and discuss recent advancements on the diverse role of inflammasomes in cancer that have underpinned their potential targeting in diverse malignancies.

Abstract

Dysregulated activation of the innate immune system is a critical driver of chronic inflammation that is associated with at least 30% of all cancers. Innate immunity can also exert tumour-promoting effects (e.g. proliferation) directly on cancer cells in an intrinsic manner. Conversely, innate immunity can influence adaptive immunity-based anti-tumour immune responses via Ag-presenting dendritic cells that activate natural killer and cytotoxic T cells to eradicate tumours. While adaptive anti-tumour immunity has underpinned immunotherapy approaches with immune checkpoint inhibitors and chimeric Ag receptor-T cells, the clinical utility of innate immunity in cancer is underexplored. Innate immune responses are governed by pattern recognition receptors, which comprise several families, including Toll-like, nucleotide-binding oligomerization domain-containing (NOD)-like and absent-in-melanoma 2 (AIM2)-like receptors. Notably, a subset of NOD-like and AIM2-like receptors can form large multiprotein “inflammasome” complexes which control maturation of biologically active IL-1β and IL-18 cytokines. Over the last decade, it has emerged that inflammasomes can coordinate contrasting pro- and anti-tumour responses in cancer and non-cancer (e.g. immune, stromal) cells. Considering the importance of inflammasomes to the net output of innate immune responses, here we provide an overview and discuss recent advancements on the diverse role of inflammasomes in cancer that have underpinned their potential targeting in diverse malignancies.

참고문헌 (125)

  1. Greten FR, "Inflammation and cancer : triggers, mechanisms, and consequences", Immunity, 51, pp.27~41 (2019)
  2. Hou J, "Targeting cancer-promoting inflammation-have anti-inflammatory therapies come of age?", Nat Rev Clin Oncol, 18, pp.261~279 (2021)
  3. Hanahan D, "Hallmarks of cancer : new dimensions", Cancer Discov, 12, pp.31~46 (2022)
  4. Jones SA, "Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer", Nat Rev Immunol, 18, pp.773~789 (2018)
  5. Shalapour S, "Pas de deux : control of anti-tumor immunity by cancer-associated inflammation", Immunity, 51, pp.15~26 (2019)
  6. Wei J, "Critical role of dendritic cell-derived IL-27 in antitumor immunity through regulating the recruitment and activation of NK and NKT cells", J Immunol, 191, pp.500~508 (2013)
  7. Yi M, "Exploiting innate immunity for cancer immunotherapy", Mol Cancer, 22, pp.187~ (2023)
  8. Moynihan KD, "Roles for innate immunity in combination immunotherapies", Cancer Res, 77, pp.5215~5221 (2017)
  9. Oft M, "IL-10 : master switch from tumor-promoting inflammation to antitumor immunity", Cancer Immunol Res, 2, pp.194~199 (2014)
  10. Holder AM, "Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours", Nat Rev Cancer, 24, pp.498~512 (2024)
  11. Guha P, "Assessing the future of solid tumor immunotherapy", Biomedicines, 10, pp.655~ (2022)
  12. Lanier OL, "Immunotherapy approaches for hematological cancers", iScience, 25, pp.105326~ (2022)
  13. Fenis A, "New immune cell engagers for cancer immunotherapy", Nat Rev Immunol, 24, pp.471~486 (2024)
  14. Man SM, "Context-dependent functions of pattern recognition receptors in cancer", Nat Rev Cancer, 22, pp.397~413 (2022)
  15. Cao X, "Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease", Nat Rev Immunol, 16, pp.35~50 (2016)
  16. Smith S, "Role of DNA", RNA sensors and contribution to autoimmunity, 2014, pp.25, 745~757
  17. Saxena M, "NOD-like receptors : master regulators of inflammation and cancer", Front Immunol, 5, pp.327~ (2014)
  18. O’Neill LA, "The history of Toll-like receptors-redefining innate immunity", Nat Rev Immunol, 13, pp.453~460 (2013)
  19. Sharma BR, "Role of AIM2 inflammasome in inflammatory diseases, cancer and infection", Eur J Immunol, 49, pp.1998~2011 (2019)
  20. Rehwinkel J, "RIG-I-like receptors : their regulation and roles in RNA sensing", Nat Rev Immunol, 20, pp.537~551 (2020)
  21. Bautista-Hernández LA, "Fibroblasts : the unknown sentinels eliciting immune responses against microorganisms", Eur J Microbiol Immunol(Bp), 7, pp.151~157 (2017)
  22. Mansell A, "Dangerous liaisons between interleukin-6 cytokine and toll-like receptor families : a potent combination in inflammation and cancer", Cytokine Growth Factor Rev, 24, pp.249~256 (2013)
  23. Drouin M, "C-Type Lectin-Like Receptors : Head or Tail in Cell Death Immunity", Front Immunol, 11, pp.251~ (2020)
  24. Dawson RE, "STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis", Gut, 71, pp.1515~1531 (2022)
  25. Tye H, "STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation", Cancer Cell, 22, pp.466~478 (2012)
  26. West AC, "Inflammatory and non-inflammatory roles for Toll-like receptors in gastrointestinal cancer", Curr Pharm Des, 21, pp.2968~2977 (2015)
  27. Malik A, "Inflammasome activation and assembly at a glance", J Cell Sci, 130, pp.3955~3963 (2017)
  28. Latz E, "Activation and regulation of the inflammasomes", Nat Rev Immunol, 13, pp.397~411 (2013)
  29. Vance RE, "The NAIP", NLRC4 inflammasomes, 2015, pp.32, 84~89
  30. Tartey S, "Inflammasomes in the pathophysiology of autoinflammatory syndromes", J Leukoc Biol, 107, pp.379~391 (2020)
  31. Martinon F, "The inflammasome : a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta", Mol Cell, 10, pp.417~426 (2002)
  32. Deswaerte V, "Transcriptional regulation of inflammasome-associated pattern recognition receptors, and the relevance to disease pathogenesis", Mol Immunol, 86, pp.3~9 (2017)
  33. Karki R, "Diverging inflammasome signals in tumorigenesis and potential targeting", Nat Rev Cancer, 19, pp.197~214 (2019)
  34. Kolb R, "Inflammasomes in cancer : a double-edged sword", Protein Cell, 5, pp.12~20 (2014)
  35. Das S, "Tumor cell-derived IL1β promotes desmoplasia and immune suppression in pancreatic cancer", Cancer Res, 80, pp.1088~1101 (2020)
  36. Deswaerte V, "Inflammasome adaptor ASC suppresses apoptosis of gastric cancer cells by an IL18-mediated inflammation-independent mechanism", Cancer Res, 78, pp.1293~1307 (2018)
  37. Tu S, "Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice", Cancer Cell, 14, pp.408~419 (2008)
  38. Wong CC, "Inhibition of IL1β by canakinumab may be effective against diverse molecular subtypes of lung cancer : an exploratory analysis of the CANTOS trial", Cancer Res, 80, pp.5597~5605 (2020)
  39. Briukhovetska D, "Interleukins in cancer : from biology to therapy", Nat Rev Cancer, 21, pp.481~499 (2021)
  40. Sun R, "The IL-1 family in tumorigenesis and antitumor immunity", Semin Cancer Biol, 86, pp.280~295 (2022)
  41. Centola M, "The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators", Blood, 95, pp.3223~3231 (2000)
  42. Amarante-Mendes GP, "Pattern recognition receptors and the host cell death molecular machinery", Front Immunol, 9, pp.2379~ (2018)
  43. Lieberman J, "Gasdermin D activity in inflammation and host defense", Sci Immunol, 4, pp.eaav1447~ (2019)
  44. Rühl S, "Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+)efflux", Eur J Immunol, 45, pp.2927~2936 (2015)
  45. Kayagaki N, "Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling", Nature, 526, pp.666~671 (2015)
  46. Masumoto J, "ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells", J Biol Chem, 274, pp.33835~33838 (1999)
  47. Conway KE, "TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers", Cancer Res, 60, pp.6236~6242 (2000)
  48. Lu A, "Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes", Cell, 156, pp.1193~1206 (2014)
  49. Franklin BS, "The intra-and extracellular functions of ASC specks", Immunol Rev, 281, pp.74~87 (2018)
  50. Franklin BS, "The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation", Nat Immunol, 15, pp.727~737 (2014)
  51. Sundaram B, "The NLR family of innate immune and cell death sensors", Immunity, 57, pp.674~699 (2024)
  52. Barnett KC, "A 360° view of the inflammasome : mechanisms of activation, cell death, and diseases", Cell, 186, pp.2288~2312 (2023)
  53. Mitchell PS, "The NLRP1 inflammasome : new mechanistic insights and unresolved mysteries", Curr Opin Immunol, 60, pp.37~45 (2019)
  54. O’Keefe ME, "Post-translational control of NLRP3 inflammasome signaling", J Biol Chem, 300, pp.107386~ (2024)
  55. Li Y, "Cryo-EM structures of ASC and NLRC4 CARD filaments reveal a unified mechanism of nucleation and activation of caspase-1", Proc Natl Acad Sci U S A, 115, pp.10845~10852 (2018)
  56. Hornung V, "AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC", Nature, 458, pp.514~518 (2009)
  57. Chou WC, "AIM2 in regulatory T cells restrains autoimmune diseases", Nature, 591, pp.300~305 (2021)
  58. Sagulenko V, "AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC", Cell Death Differ, 20, pp.1149~1160 (2013)
  59. Heilig R, "Function and mechanism of the pyrin inflammasome", Eur J Immunol, 48, pp.230~238 (2018)
  60. Xu H, "Innate immune sensing of bacterial modifications of Rho GTPases by the pyrin inflammasome", Nature, 513, pp.237~241 (2014)
  61. Villani AC, "Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility", Nat Genet, 41, pp.71~76 (2009)
  62. Zaki MH, "The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis", Immunity, 32, pp.379~391 (2010)
  63. Ratsimandresy RA, "The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18", IL-22, Cell Mol Immunol, pp.2017, 14[DOI]
  64. Chen L, "NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth", Nat Immunol, 18, pp.541~551 (2017)
  65. Normand S, "Nod-like receptor pyrin domain-containing protein 6(NLRP6)controls epithelial self-renewal and colorectal carcinogenesis upon injury", Proc Natl Acad Sci U S A, 108, pp.9601~9606 (2011)
  66. Elinav E, "NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis", Cell, 145, pp.745~757 (2011)
  67. Noto JM, "Research and Clinical Applications of Targeting Gastric Neoplasms", pp.91~118 (2021), Academic Press
  68. Benoit BN, "Role of ASC in the mouse model of Helicobacter pylori infection", J Histochem Cytochem, 57, pp.327~338 (2009)
  69. Semper RP, "Helicobacter pylori-induced IL-1β secretion in innate immune cells is regulated by the NLRP3 inflammasome and requires the cag pathogenicity island", J Immunol, 193, pp.3566~3576 (2014)
  70. Dawson RE, "The cytosolic DNA sensor AIM2 promotes Helicobacter-induced gastric pathology via the inflammasome", Immunol Cell Biol, 101, pp.444~457 (2023)
  71. Semper RP, "Helicobacter pylori exploits the NLRC4 inflammasome to dampen host defenses", J Immunol, 203, pp.2183~2193 (2019)
  72. Zhong FL, "Germline NLRP1 mutations cause skin inflammatory and cancer susceptibility syndromes via inflammasome activation", Cell, 167, pp.187~202 (2016)
  73. Velloso FJ, "NOD-like receptors : major players(and targets)in the interface between innate immunity and cancer", Biosci Rep, 39, pp.BSR20181709~ (2019)
  74. Protti MP, "Dual role of inflammasome adaptor ASC in cancer", Front Cell Dev Biol, 8, pp.40~ (2020)
  75. Rébé C, "Interleukin-1β and cancer", Cancers(Basel), 12, pp.1791~ (2020)
  76. Fabbi M, "Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP", J Leukoc Biol, 97, pp.665~675 (2015)
  77. Liu W, "Dual role of apoptosis-associated speck-like protein containing a CARD(ASC)in tumorigenesis of human melanoma", J Invest Dermatol, 133, pp.518~527 (2013)
  78. Virmani A, "Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer", Int J Cancer, 106, pp.198~204 (2003)
  79. Sand J, "The NLRP1 inflammasome pathway is silenced in cutaneous squamous cell carcinoma", J Invest Dermatol, 139, pp.1788~1797 (2019)
  80. Koizumi M, "Apoptosis-associated speck-like protein containing a CARD regulates the growth of pancreatic ductal adenocarcinoma", Sci Rep, 11, pp.22351~ (2021)
  81. Ungerbäck J, "Genetic variation and alterations of genes involved in NFκB", TNFAIP3-and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer, 2012, pp.33, 2126~2134
  82. Cambui RAG, "Double-edged sword of inflammasome genetics in colorectal cancer prognosis", Clin Immunol, 213, pp.108373~ (2020)
  83. Shi F, "Low NLRP3 expression predicts a better prognosis of colorectal cancer", Biosci Rep, 41, pp.BSR20210280~ (2021)
  84. Williams TM, "The NLRP1 inflammasome attenuates colitis and colitis-associated tumorigenesis", J Immunol, 194, pp.3369~3380 (2015)
  85. Liu R, "Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer : correlation with cancer stages and inflammasome components", Oncotarget, 6, pp.33456~33469 (2015)
  86. Domblides C, "Human NLRC4 expression promotes cancer survival and associates with type I interferon signaling and immune infiltration", J Clin Invest, 134, pp.e166085~ (2024)
  87. Shen E, "Low expression of NLRP1 is associated with a poor prognosis and immune infiltration in lung adenocarcinoma patients", Aging(Albany NY), 13, pp.7570~7588 (2021)
  88. Sharma D, "Pyrin inflammasome regulates tight junction integrity to restrict colitis and tumorigenesis", Gastroenterology, 154, pp.948~964 (2018)
  89. Oktenli C, "High frequency of inherited variants in the MEFV gene in patients with hematologic neoplasms : a genetic susceptibility?", Int J Hematol, 95, pp.380~385 (2012)
  90. Alanazi M, "Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes", Cancer Sci, 115, pp.1834~1850 (2024)
  91. Qi M, "AIM2 promotes the development of non-small cell lung cancer by modulating mitochondrial dynamics", Oncogene, 39, pp.2707~2723 (2020)
  92. Nakamura Y, "Overexpression of absent in melanoma 2 in oral squamous cell carcinoma contributes to tumor progression", Biochem Biophys Res Commun, 509, pp.82~88 (2019)
  93. Li C, "PINK1 and PARK2 suppress pancreatic tumorigenesis through control of mitochondrial iron-mediated immunometabolism", Dev Cell, 46, pp.441~455 (2018)
  94. Farshchian M, "Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma", Oncotarget, 8, pp.45825~45836 (2017)
  95. Woerner SM, "The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers", Genes Chromosomes Cancer, 46, pp.1080~1089 (2007)
  96. Dihlmann S, "Lack of absent in melanoma 2(AIM2)expression in tumor cells is closely associated with poor survival in colorectal cancer patients", Int J Cancer, 135, pp.2387~2396 (2014)
  97. Lozano-Ruiz B, "The emerging relevance of AIM2 in liver disease", Int J Mol Sci, 21, pp.6535~ (2020)
  98. Daley D, "NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma", J Exp Med, 214, pp.1711~1724 (2017)
  99. Allen IC, "The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer", J Exp Med, 207, pp.1045~1056 (2010)
  100. Zaki MH, "IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation", J Immunol, 185, pp.4912~4920 (2010)
  101. Drexler SK, "Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis", Proc Natl Acad Sci U S A, 109, pp.18384~18389 (2012)
  102. Zhu Q, "Cutting edge : distinct regulatory mechanisms control proinflammatory cytokines IL-18 and IL-1β", J Immunol, 198, pp.4210~4215 (2017)
  103. Yao X, "Remodelling of the gut microbiota by hyperactive NLRP3 induces regulatory T cells to maintain homeostasis", Nat Commun, 8, pp.1896~ (2017)
  104. Hu B, "Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4", Proc Natl Acad Sci U S A, 107, pp.21635~21640 (2010)
  105. Chow MT, "NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma", Immunol Cell Biol, 90, pp.983~986 (2012)
  106. West AJ, "Inflammasome-associated gastric tumorigenesis is independent of the NLRP3 pattern recognition receptor", Front Oncol, 12, pp.830350~ (2022)
  107. Dupaul-Chicoine J, "The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity", Immunity, 43, pp.751~763 (2015)
  108. Hu B, "Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer", Proc Natl Acad Sci U S A, 110, pp.9862~9867 (2013)
  109. Kolb R, "Obesity-associated NLRC4 inflammasome activation drives breast cancer progression", Nat Commun, 7, pp.13007~ (2016)
  110. Ohashi K, "NOD-like receptor C4 inflammasome regulates the growth of colon cancer liver metastasis in NAFLD", Hepatology, 70, pp.1582~1599 (2019)
  111. Man SM, "Critical role for the DNA sensor AIM2 in stem cell proliferation and cancer", Cell, 162, pp.45~58 (2015)
  112. Wilson JE, "Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt", Nat Med, 21, pp.906~913 (2015)
  113. Martínez-Cardona C, "AIM2 deficiency reduces the development of hepatocellular carcinoma in mice", Int J Cancer, 143, pp.2997~3007 (2018)
  114. Ma X, "Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway", Oncotarget, 7, pp.36185~36197 (2016)
  115. Coll RC, "MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition", Nat Chem Biol, 15, pp.556~559 (2019)
  116. Chen L, "Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma", Cell Mol Life Sci, 75, pp.2045~2058 (2018)
  117. Theivanthiran B, "A tumor-intrinsic PD-L1", NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy, 2020, pp.130, 2570~2586
  118. Tengesdal IW, "Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion", Proc Natl Acad Sci U S A, 118, pp.e2000915118~ (2021)
  119. Amo-Aparicio J, "Pancreatic ductal adenocarcinoma cells regulate NLRP3 activation to generate a tolerogenic microenvironment", Cancer Res Commun, 3, pp.1899~1911 (2023)
  120. Tengesdal IW, "Activation of host-NLRP3 inflammasome in myeloid cells dictates response to anti-PD-1 therapy in metastatic breast cancers", Pharmaceuticals(Basel), 15, pp.574~ (2022)
  121. Bruchard M, "Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth", Nat Med, 19, pp.57~64 (2013)
  122. Wang C, "Chemotherapy activates inflammasomes to cause inflammation-associated bone loss", Elife, 13, pp.RP92885~ (2024)
  123. Bertheloot D, "Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo", EMBO Mol Med, 14, pp.e15415~ (2022)
  124. Garlanda C, "Interleukin-1 in tumor progression, therapy, and prevention", Cancer Cell, 39, pp.1023~1027 (2021)
  125. Landy E, "Biological and clinical roles of IL-18 in inflammatory diseases", Nat Rev Rheumatol, 20, pp.33~47 (2024)

관련 논문AI추천

Regulatory Roles of the Caspase-11 Non-Canonical Inflammasome in Inflammatory Diseases이영수대한면역학회 · Immune Network2018 · 제18권 제6호The Role of NLR-related Protein 3 Inflammasome in Host Defense and Inflammatory Diseases신동민, 양철수, 조은경대한배뇨장애요실금학회 · International Neurourology Journal2012 · 제16권 제1호Immunogenic cell death in cancer immunotherapy차종호, Chae-Eun Lee, Jisoo Shin, Joo-Yoon Chung, Minji Choi, Minji Kim, Wen-Hao Yang, Xiuwen Yan생화학분자생물학회 · BMB Reports2023 · 제56권 제5호The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets이흥규, Chae Won Kim, Kyun-Do Kim생화학분자생물학회 · BMB Reports2021 · 제54권 제1호Immune Response and the Tumor Microenvironment: How They Communicate to Regulate Gastric Cancer남기택, 이근욱, 황혜경거트앤리버 소화기연관학회협의회 · Gut and Liver2014 · 제8권 제2호The Inhibitory Effect of NLRP3 Deficiency in Hepatocellular Carcinoma SK-Hep1 Cells조효선, 최원혁한국미생물·생명공학회 · 한국미생물·생명공학회지2021 · 제49권 제4호

이 간행물의 다른 논문 (5건)

Increased Inflammatory Responses in Patients With Active Disseminated Non-Tuberculous Mycobacterial Infection and High Anti-Interferon-Gamma AutoantibodiesPattaraporn Srisai, Chanchai Hongsa, Yothin Hinwan, Varis Manbenmad, Ploenchan Chetchotisakd, Siriluck Anunnatsiri, Kiatichai Faksri, Todsapol Techo, Kanin Salao, Steven W. Edwards, Arnone Nithichanonpp. 1-19Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46민도식, 신민화, Eunha Ohpp. 1-20Efficient In Vitro Plasma Cell Differentiation by B Cell Receptor Activation and Cytokine StimulationHyun-Sup Song, You-Me Kimpp. 1-17Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment DecisionsReinhart Speeckaert, Arno Belpaire, Jo Lambert, Marijn Speeckaert, Nanja van Geelpp. 1-21STING-STAT6 Signaling Pathway Promotes IL-4+ and IFN-α+ Fibrotic T Cell Activation and Exacerbates Scleroderma in SKG MiceJeong Won Choi, Jeehee Youn, Ha Yeon Jeong, Kun Hee Lee, Jin Seok Woo, Chul Hwan Bang, Sung-Hwan Park, Mi-La Chopp. 1-17
원문 보기